In silico analysis of miRNA-mRNA pair(s) in metabolic syndrome and Parkinson's: Molecular links and potential biomarkers
DOI:
https://doi.org/10.25170/djm.v23i3.5606Keywords:
ATP2B4, biomarker, hsa-miR-631, Parkinson, sindrom metabolikAbstract
Introduction: Parkinson's disease (PD) is the second most common neurodegenerative disease. Identification of PD biomarkers is critical for early diagnosis and development of therapeutic targets. There are many factors that are associated with PD, including metabolic syndrome (MetS). However, molecular links between MetS and PD for biomarkers is still a challenge. This study aims to determine the molecular links between MetS and PD using an in silico approach.
Methods: Data were obtained from Gene Expression Omnibus to identify differentially expressed genes (DEGs) and microRNA (DEMs) in PD and MetS. DEGs were mapped to protein-protein interaction (PPI) networks using the STRING platform. Then, gene ontology (GO) and pathway analysis was performed with EnrichR to reveal specific and overlapped biological processes. Finally, microRNA (miRNA) and mRNA pairs were predicted using TargetScan.
Results: A total of 25 DEGs were identified in both MetS and PD. GO and pathway analysis for MetS-PD revealed that these DEGs mainly related to metabolic and cytokine pathways. Examination of miRNA showed that hsa-miR-631 was down-regulated in both MetS and PD. GO and pathway analysis on predicted targets of hsa-miR-631 showed major changes in metabolic pathways. Hsa-miR-631 can target the 3' UTR of ATP2B4 at poorly conserved site, indicating a specific miRNA-mRNA pairing in humans.
Conclusion: In patients with MetS and PD, hsa-miR-631 and ATP2B4 are depleted and elevated, respectively. Bioinformatic analysis indicates that ATP2B4 is a target of hsa-miR-631. We demonstrate for the first time that hsa-miR-631/ ATP2B4 pair is potential biomarker for PD due to MetS.
Downloads
References
DeMaagd G, Philip A. Parkinson’s disease and its management: Part 1: Disease entity, risk factors, pathophysiology, clinical presentation, and diagnosis. PT. 2015 Aug 1;40(8):504-32.
Aarsland D, Batzu L, Halliday GM, Geurtsen GJ, Ballard C, Ray CK, et al. Parkinson disease-associated cognitive impairment. Nat Rev Dis Prim. 2021 July 1;7(1):47.
Goedert M, Masuda-Suzukake M, Falcon B. Like prions: the propagation of aggregated tau and α-synuclein in neurodegeneration. Brain. 2017 Feb 1;140(2):266-78.
Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson’s disease. Lancet Neurol. 2021 May 1;20(5):385-97.
Leehey M, Luo S, Sharma S, et al. Association of metabolic syndrome and change in Unified Parkinson’s Disease Rating Scale scores. Neurology. 2017 Sep 29;89(17):1789-94.
Sharma S, Oakes D, Eberly S, Singer C, Jillian L, Simuni T. Association between metabolic syndrome and progression in Parkinson’s disease. Clin Epidemiol Glob Heal. 2023 Sept 9;24:101409.
Brown AE, Walker M. Genetics of insulin resistance and the metabolic syndrome. Curr Cardiol Rep. 2016 June 16;18(8):75.
Herrero MT, Estrada C, Maatouk L, Vyas S. Inflammation in Parkinson's disease: role of glucocorticoids. Front Neuroanat. 2015 Apr 2;9:32.
Nam GE, Kim SM, Han K, Kim NH, Chung HS, Kim JW, et al. Metabolic syndrome and risk of Parkin-son disease: A nationwide cohort study. PLoS Med. 2018 Aug 21;15(8):e1002640.
Roh JH, Lee S, Yoon JH. Metabolic syndrome and Parkinson’s disease incidence: A nationwide study using propensity score matching. Metab Syndr Relat Disord. 2021 Feb 2;19(1):1-7.
Peng Z, Zhou R, Liu D, Cui M, Yu K, Yang H, et al. Association between metabolic syndrome and mild Parkinsonian signs progression in the elderly. Front Aging Neurosci. 2021 Oct 1;13:722836.
Li LY, Liu SF, Zhuang JL, Li MM, Huang ZP, Chen YH, et al. Recent research progress on metabolic syndrome and risk of Parkinson's disease. Rev Neurosci. 2022 Dec 2;34(7):719-35.
Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5.
D'Amore S, Härdfeldt J, Cariello M, Graziano G, Copetti M, Di Tullio G, et al. Identification of miR-9-5p as direct regulator of ABCA1 and HDL-driven reverse cholesterol transport in circulating CD14+ cells of patients with metabolic syndrome. Cardio-vasc Res. 2018 Jul 1;114(8):1154-64.
Diener C, Hart M, Kehl T, Becker-Dorison A, Tänzer T, Schub D, et al. Time-resolved RNA signatures of CD4+ T cells in Parkinson's disease. Cell Death Discov. 2023 Jan 21;9(1):18.
Cui C, Zhong B, Fan R, Cui Q. HMDD v4.0: a database for experimentally supported human microRNA-disease associations. Nucleic Acids Res. 2024 Jan 5;52(D1):D1327-32.
Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P, et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res. 2010 Jul;38(suppl_2):W214-20.
Sherman BT, Hao M, Qiu J, et al. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 2022 July 5;50(W1):W216-21.
Le W, Dong J, Li S, Korczyn AD. Can biomarkers help the early diagnosis of Parkinson’s disease? Neurosci Bull. 2017 Sep 2;33(5):535-542.
Souza APDS, Barros WMA, Silva JML, Silva MRM, Silva ABJ, Fernandes MSS, et al. Effect of metabolic syndrome on Parkinson's disease: A systematic review. Clinics (Sao Paulo). 2021 Dec 13;76:e3379.
Ho PTB, Clark IM, Le LTT. MicroRNA-based diagnosis and therapy. Int J Mol Sci. 2022 Jun 28;23(13):7167.
Cione E, Cannataro R, Gallelli L, De Sarro G, Caroleo MC. Exosome microRNAs in metabolic syndrome as tools for the early monitoring of diabetes and possible therapeutic options. Pharmaceuticals. 2021 Dec 2;14(12):1257.
Azam HMH, Rößling RI, Geithe C, et al. MicroRNA biomarkers as next-generation diagnostic tools for neurodegenerative diseases: A comprehensive review. Front Mol Neurosci. 2024 May 31;17.
Han Q, Zhang Y, Jiao T, Li Q, Ding X, Zhang D, et al. Urinary sediment microRNAs can be used as potential noninvasive biomarkers for diagnosis, reflecting the severity and prognosis of diabetic nephropathy. Nutr Diabetes. 2021 June 30;11(1):24.
Hattangady NG, Foster J, Lerario AM, Ponce-Balbuena D, Rege J, Monticone S, et al. Molecular and electrophysiological analyses of ATP2B4 gene variants in bilateral adrenal hyperaldosteronism. Horm Cancer. 2020 Feb;11(1):52-62.
Cao J, Zhu Q, Liu L, Glazier BJ, Hinkel BC, Liang C, et al. Global Transcriptome analysis of brown adipose tissue of diet-induced obese mice. Int J Mol Sci. 2018 Apr 6;19(4):1095.
Zaichick S V., McGrath KM, Caraveo G. The role of Ca2+ signaling in Parkinson’s disease. Dis Model Mech. 2017 May 1;10(5):519-535.
Franco R. Metabolic dysfunction in Parkinson's disease: bioenergetics, redox homeostasis and central carbon metabolism. Brain Res Bull. 2017 Jul;133:12-30.
Lasselin J, Capuron L. Chronic low-grade inflammation in metabolic disorders: Relevance for behavioral symptoms. Neuroimmunomodulation. 2014 Feb 14;21(2-3):95-101.
Troncoso-Escudero P, Parra A, Nassif M, Vidal RL. Outside in: Unraveling the role of neuroinflammation in the progression of Parkinson’s Disease. Front Neurol. 2018 Oct 15;9.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Damianus Journal of Medicine
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
